Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents

Alam, Rizwan; Wahi, Divya; Singh, Rashmi; Sinha, Devapriya; Tandon, Vibha; Grover, Abhinav; Uddin, Rahis

doi:10.1016/j.bioorg.2016.10.001

Cited by 81 publications

(45 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially, 3-aryl-1-phenylpyrazole-4-carbaldehydes 4(a-f) were synthesized from phenylhydrazones 3(af) by Vilsmeier-Haack formylation as reported by Raquib Alam et al [20]. Then 3-aryl-1-phenylpyrazole-4-carbaldehydes 4(a-f) were condensed with isoniazid 5 and 3-fluoro-4-morpholinoaniline 6 which gives corresponding imines 7(a-f) and 8(a-f) respectively.…”

Section: Chemistrymentioning

confidence: 99%

Development of New Pyrazole Hybrids as Antitubercular Agents: Synthesis, Biological Evaluation and Molecular Docking Study

Shaikh¹,

Zaheer²,

Mokale³

et al. 2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Synthesis of new 1, 3-diphenyl pyrazole derivatives 9(a-f) and 10(a-f) using molecular hybridization approach and evaluation of their antitubercular and cytotoxic studies. Methods:The structures of synthesized compounds were confirmed by 1 H NMR, 13 C NMR and mass spectra. The antitubercular activity of compounds and standard drugs were assessed against Mycobacterium tuberculosis using Microplate alamar blue assay (MABA). The cytotoxic activities were performed by Sulforhodamine B (SRB) assay. The molecular docking and in silico ADME prediction studies were also performed by using Schrodinger. Results:The results reveal that compounds 9c, 9d, 10c and 10d exhibited substantial antitubercular potential with MIC<20 μM. The cytotoxic studies revealed that active compounds (9c, 9d, 10c and 10d) are non-toxic to HeLa cancer cell lines with the selectivity index>10. The molecular docking study was performed to study the binding orientation and affinity of synthesized compounds for InhA enzyme. Conclusion:The study explored that 1, 3-diphenyl pyrazole hybrid coupled with well-known antitubercular drugs could be a potential lead for antitubercular agents. In silico molecular docking, study helps to identify their corresponding intermolecular ligand-protein interactions with target enzyme. Also, ADME prediction studies revealed that the compounds were in acceptable range to have good pharmacokinetic parameters.

show abstract

Section: Chemistrymentioning

confidence: 99%

Development of New Pyrazole Hybrids as Antitubercular Agents: Synthesis, Biological Evaluation and Molecular Docking Study

Shaikh¹,

Zaheer²,

Mokale³

et al. 2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

“…Globally, cancer is the second major cause of increasing mortality rate after cardiovascular diseases [21] despite many treatments such as chemotherapy [22 -23]. Pyrazole ring containing drugs have made a unique space in field of medicinal chemistry in competition of other drugs for cancer treatment such as Crizotinib and Encorafinib [24 -27].…”

Section: Anticancer Activitymentioning

confidence: 99%

Pyrazole Bearing Molecules as Bioactive Scaffolds: A Review

Aziz

Zahoor

Ahmad

2020

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

Pyrazole being a heterocyclic motif has secured an eccentric status in the field of medicinal chemistry. Pyrazole and its derivatives have tremendous biological applications like anti-cancer, anti-microbial, antiviral, antifungal, anti-inflammatory, analgesic, insecticidal etc. In this review, some recent developments have been reported for the synthesis of biologically active pyrazole based molecules having biological potential such as anti-SIRT1 and SIRT2, anti-FAAH, anti-NOSs, as liver X receptor partial agonist, CB2 receptor ligand and glucagon receptor antagonists.

show abstract

“…Two series of substituted phenyl pyrazoles were developed by Alam et al and were tested as inhibitor for several cancer cell lines [3]. As a result, compound 39 displayed superior cytotoxicity with an IC 50 value of 14.31 ± 0.90 µM for MCF-7, 8.55 ± 0.35 µM for NCI-H460, and 7.01 ± 0.60 µM for HeLa.…”

Section: Discovery Of Some Pyrazoles In the Year 2016mentioning

confidence: 99%

“…Pyrazole represents one of the most prominent classes of heterocycles exhibiting large spectrum of biological performances such as anticancer [3,4], antitumor [5], anti-AIDS [6], antimicrobial [7,8], antimalarial [9], and antitubercular [10]. It gained great attention since the privileged structure is commonly found as active constituent in commercial drugs ( Fig.…”

Section: Introductionmentioning

confidence: 99%

Recent Reports on Pyrazole-Based Bioactive Compounds as Candidate for Anticancer Agents

Ardiansah

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Pyrazole is a five-membered heterocyclic compound containing two nitrogen atoms. Due to its biological significance, design of novel pyrazole derivatives has become an interesting research area. We report the current progress in the development of anticancer agents containing pyrazole ring covering the time span of the past few years (2013)(2014)(2015)(2016). The presence of this nucleus is accompanied with some side chains, functional groups, or in combination with other nucleus such as thiazole, thiourea, glucosamine, naphthalimide, and benzofuran. Several biologically active pyrazoles synthesized by numerous researchers across the world are summarized in this paper.

show abstract

Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents

Cited by 81 publications

References 72 publications

Development of New Pyrazole Hybrids as Antitubercular Agents: Synthesis, Biological Evaluation and Molecular Docking Study

Development of New Pyrazole Hybrids as Antitubercular Agents: Synthesis, Biological Evaluation and Molecular Docking Study

Pyrazole Bearing Molecules as Bioactive Scaffolds: A Review

Recent Reports on Pyrazole-Based Bioactive Compounds as Candidate for Anticancer Agents

Contact Info

Product

Resources

About